Drug Profile

GFS 202A

Alternative Names: GFS-202A

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GenFleet Therapeutics
Class Bispecific antibodies
Mechanism of Action Growth differentiation factor 15 inhibitors; Interleukin 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cachexia

Most Recent Events

25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Cachexia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
24 Apr 2025 Phase-I clinical trials in Cachexia in China (IV) (NCT06898255)
27 Mar 2025 Genfleet Therapeutics plans a phase I trial for Cachexia in China (IV, Injection) (NCT06898255)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com